Molecular Devices Introduces FLIPR Tetra(TM) Screening System with Simultaneous 1536 Liquid Transfer

Molecular Devices Introduces FLIPR Tetra(TM) Screening System
with Simultaneous 1536 Liquid Transfer 


SUNNYVALE, Calif., June 1  /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the introduction of FLIPR Tetra(TM),
the first system that enables researchers to significantly increase throughput
of cell-based assays by measuring 1536 kinetic measurements simultaneously.

The FLIPR Tetra, which debuts today at Molecular Devices' Drug Discovery
Conference in Berkeley, California, is the only microplate detection system
that simultaneously transfers liquid to 1536-well microplates, significantly
reducing screening time and reagent consumption. This entirely new, modular
system also offers traditional 96- and 384-well fluidics, easily convertible by
the user within minutes, providing a seamless transition between higher- volume
assays to those that require sub-microliter volume additions. FLIPR Tetra is
also the first FLIPR(R) system to offer an expanded set of excitation
wavelengths, significantly broadening its use beyond traditional calcium
mobilization and membrane potential assays.

"FLIPR is the most widely-used screening system for GPCR analysis," stated
Michael L. Biros, Marketing Director for Drug Discovery Instruments at
Molecular Devices. "With FLIPR Tetra, researchers can now increase the
throughput and reduce the cost of their calcium mobilization and membrane
potential assays even more-screening over 3,000 kinetic assays every six
minutes using a few thousand cells per assay."

Commenting on the launch of the FLIPR Tetra, Stephen J. Oldfield, Ph.D.,
Molecular Devices' Vice President of Worldwide Marketing, stated, "Development
of FLIPR Tetra was guided by senior-level drug discovery managers striving to
reduce facilities and screening costs, as well as thousands of FLIPR users
looking to improve ease-of-use and robustness. Oldfield further noted, "The
FLIPR Tetra brings the multi-wavelength capability that our FlexStation(TM)
users have enjoyed to a high-throughput platform, paving the way for multi-
wavelength applications. This new instrument platform also extends the user
base for our growing family of reagent kits, including Calcium 3 and membrane
potential kits."

Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research.  The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high-throughput and
cost-effective identification and evaluation of drug candidates.  The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry.  Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.

This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the FLIPR Tetra
system. Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "will," and similar
expressions are intended to identify forward-looking statements. There are a
number of important factors that could cause the results of Molecular Devices
Corporation to differ materially from those indicated by these forward-looking
statements, including, among others, risks detailed from time to time in the
Company's SEC reports, including its Annual Report on Form 10-K for the year
ended December 31, 2003, as amended, and its quarterly report on Form 10-Q for
the quarter ended March 31, 2004.  Molecular Devices Corporation does not
undertake any obligation to update forward-looking statements. 

DATASOURCE: Molecular Devices Corporation



CONTACT:  Tim Harkness of Molecular Devices Corporation, [phone]



Web site:  http://www.moleculardevices.com/ 

Copyright